Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Paused · Phase 2 · Has a placebo group

Conditions studied: Carcinoma, Renal Cell, Kidney Neoplasms

In brief

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Key facts

Study ID: NCT00065572
Run by: AstraZeneca
Starts: 2003-08-01
Expected to finish: 2004-02-01
Last updated by the study team: 2011-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Newly diagnosed metastatic renal cell carcinoma
Suitable for nephrectomy

You may not qualify if…

Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
Significant cardiac event within 3 months of entry
Any history of coronary angioplasty or history of myocardial infarction

Where it is running

Research Site — Los Angeles, California, United States
Research Site — Newark, Delaware, United States
Research Site — Tampa, Florida, United States
Research Site — Chicago, Illinois, United States
Research Site — Indianapolis, Indiana, United States
Research Site — Baltimore, Maryland, United States
Research Site — St Louis, Missouri, United States
Research Site — Lebanon, New Hampshire, United States
Research Site — Hackensack, New Jersey, United States
Research Site — Rochester, New York, United States
Research Site — The Bronx, New York, United States
Research Site — Cleveland, Ohio, United States
Research Site — Portland, Oregon, United States
Research Site — Philadelphia, Pennsylvania, United States
Research Site — Nashville, Tennessee, United States
Research Site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.